Story continues below

Item 7.01

Regulation FD Disclosure.
BioRestorative Therapies, Inc. (the “Company”) has prepared
presentation materials (the “Presentation Materials”) that
management intends to use from time to time on and after June 15,
2017 in presentations about the Company’s business. The Company
intends to use the Presentation Materials, possibly with
modification, at the Marcum Microcap Conference being held on
June 15, 2017 and June 16, 2017 and may use the Presentation
Materials in other presentations to current and potential
investors, lenders, creditors, insurers, vendors, customers,
employees and others with an interest in the Company and its
The information contained in the Presentation Materials is
summary information that should be considered in the context of
the Company’s filings with the Securities and Exchange
Commission and other public announcements that the Company may
make by press release or otherwise from time to time. The
Presentation Materials speak as of the date of this Current
Report on Form 8-K. While the Company may elect to update the
Presentation Materials in the future to reflect events and
circumstances occurring or existing after the date of this
Current Report on Form 8-K, the Company specifically disclaims
any obligation to do so. The Presentation Materials are furnished
as Exhibit 99.1 to this Current Report on Form 8-K and are
incorporated herein by reference. The presentation materials will
also be posted in the Investor Relations section of the
Company’s website, for 90 days.
The information referenced under Item 7.01 (including Exhibit
99.1 referenced in Item 9.01 below) of this Current Report on
Form 8-K is being “furnished” under “Item 7.01. Regulation FD
Disclosure” and, as such, shall not be deemed to be “filed”
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that
section. The information set forth in this Current Report on Form
8-K (including Exhibit 99.1 referenced in Item 9.01 below) shall
not be incorporated by reference into any registration statement,
report or other document filed by the Company to the Securities
Act of 1933, as amended, except as shall be expressly set forth
by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1 Presentation Materials.


BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.

An ad to help with our costs